Erectile Dysfunction: Causes, Diagnosis, and Step-by-Step Management for Physicians

1. Introduction: Erectile Dysfunction Overview

Definition of Erectile Dysfunction

Erectile Dysfunction (ED) or impotence is clinically defined as the consistent or recurrent inability to acquire or sustain a penile erection of sufficient rigidity and duration for successful vaginal penetration and sexual intercourse. 

Clinicians must meticulously distinguish ED from "loss of libido," which refers to sexual dysfunction resulting from a deficit in sexual desire or drive, often an early manifestation of depressive illness.

Epidemiology 

ED is a highly prevalent condition with a clear age-stratified progression. A multinational study of nearly 28,000 men identified an overall prevalence of 16%.

• Ages 20–30: 8% prevalence.
• Ages 70–75: 37% prevalence.

Clinical Importance 

The impact of ED extends beyond sexual function, frequently leading to profound psychological distress and marital breakdown. In diabetic populations, the onset of ED correlates with a measurable decline in quality-of-life scores and an increase in depressive symptoms.

2. Pathophysiology of Erectile Dysfunction

Neurovascular Mechanisms Erection is a vascular phenomenon triggered by neurologic signals within a specific hormonal and psychological context.

• Psychogenic Erections: Triggered by central nervous system (CNS) stimuli (visual, auditory, fantasy) relayed to the T-11 to L-2 thoracolumbar erection center.
• Reflex Erections: Generated by tactile genital stimuli via a reflex arc at the S-2 to S-4 sacral erection center.
• Nocturnal Erections: These occur 3–4 times nightly, coupled exclusively with rapid eye movement (REM) sleep. Absence suggests organic pathology or severe depression.

Nitric Oxide–cGMP Pathway The biochemical cascade is initiated by nitric oxide synthase (NOS). In the presence of oxygen and NADPH, NOS transforms arginine into citrulline and nitric oxide (NO). NO stimulates the generation of cyclic guanosine monophosphate (cGMP), which facilitates the relaxation of intracavernosal trabeculae, allowing for rapid engorgement of the corpora cavernosa.

Endothelial Dysfunction and Venous Occlusion Rigidity requires accelerated arterial inflow to increase intracavernosal pressure, which subsequently compresses the emissary veins against the tunica albuginea. Interference with oxygen delivery or NO synthesis prevents the pressure from rising sufficiently to impede this venous outflow.

Hormonal Regulation Testosterone is essential for maintaining intrapenile NOS levels and acts through psychogenic channels to enhance libido. Its secretion is regulated by the pulsatile release of gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH).

3. Classification of ED

• Organic: Resulting from physical alterations in vascular, neurologic, or endocrine systems.
• Psychogenic: Predominantly due to performance anxiety, relationship conflict, or depression. Pure psychogenic etiology is identified in less than 10% of cases.
• Mixed: Coexistence of organic and psychogenic factors, common in chronic disease states.

4. Causes of Erectile Dysfunction

Vascular

• Atherosclerosis of the hypogastric artery or feeder vessels.
• Diabetic vascular disease.
• Aortoiliac disease (Leriche’s syndrome), often presenting with buttock claudication.

Neurological

• CNS: Stroke, Multiple Sclerosis (MS), dementia, spinal cord tumors or injury.
• Peripheral: Diabetic neuropathy, spina bifida.
• Iatrogenic: Damage to the nervi erigentes during pelvic surgery (e.g., radical prostatectomy, abdominoperineal resection).

Endocrine

• Diabetes Mellitus (the most common organic cause).
• Hypogonadism, Hypothyroidism, and Hyperthyroidism.
• Cushing’s syndrome and Addison’s disease.

Drug-Induced (Sexually Noxious Substances) 

Approximately 25% of cases are medication-related:

• Antihypertensives: Thiazide diuretics (e.g., chlorthalidone), beta-blockers, and sympathetic blockers (clonidine, methyldopa).
• Antidepressants: Particularly SSRIs (fluoxetine, paroxetine) and tricyclics.
• Recreational: Nicotine, alcohol, cocaine, and heroin.
• Others: Cimetidine, ketoconazole, and estrogens.

Local and Psychological

• Local: Peyronie’s disease (fibrotic plaques), phimosis, or short frenulum.
• Psychological: Major depressive disorder and chronic stress.

5. Risk Factors for Erectile Dysfunction

• Aging and Lifestyle: Sedentary behavior, obesity, and smoking.
• Comorbidities: Hypertension, dyslipidemia, obstructive sleep apnea (OSA), and restless leg syndrome (RLS).
• Frequency of Sexual Activity: Men reporting intercourse less than once per week develop ED at twice the rate of those reporting intercourse at least once per week (79 vs. 33/1000).

6. Erectile Dysfunction as a Cardiovascular Marker

The Pathophysiologic Link ED and cardiovascular disease (CVD) share a common pathway of endothelial dysfunction. ED often precedes symptomatic CVD, serving as an early warning sign for myocardial infarction or stroke.

Clinical Implications

• Incident ED: Hazard ratio (HR) of 1.25 for subsequent CV events.
• Prevalent ED: HR of 1.45 for subsequent CV events.

Cardiovascular Risk Stratification: Physicians must stratify men with ED (without obvious cause like trauma) into risk categories prior to initiating therapy:

1. Low Risk: Asymptotic, <3 risk factors. May initiate ED therapy and lifestyle modification.
2. Intermediate Risk: Requires an exercise stress test to assess cardiac reserve before initiating therapy.
3. High Risk: Refractory angina, recent MI, or high-grade arrhythmias. Requires mandatory cardiology evaluation before any ED treatment.

7. Clinical Evaluation of ED

History

• Rapidity of Onset: Sudden onset typically indicates a psychogenic cause or specific trauma. Gradual onset suggests a progressive organic etiology (vascular or endocrine).
• Erectile Reserve: Inquire about spontaneous morning/nocturnal erections. Their presence attests to the integrity of neurologic reflexes and corpora cavernosal blood flow.
• Interpersonal Factors: Partner interviews are essential to assess relationship quality and identify potential "sensate focus" requirements.

Physical Examination

• Vascular: Palpation of femoral/peripheral pulses; auscultation for abdominal/pelvic bruits.
• Neurological: Cremasteric reflex (T-11 to L-2 integrity) and perianal sensation.
• Urologic: Palpation for Peyronie's plaques, testicular atrophy (hypogonadism), and assessment of secondary sex characteristics.

Validated Questionnaires 

The IIEF-5 (SHIM) is used to categorize severity:

8. Diagnostic Workup of ED

Laboratory Testing

• Fasting Glucose/A1c, Lipid profile, CBC, and Chemistry panel (Creatinine/LFTs).
• Endocrine Panel: Morning Serum Total Testosterone, TSH, Serum Prolactin.
• Specialized Labs: VDRL (to rule out neurosyphilis), Gonadotropin assay (FSH/LH), and Urinary/Plasma Cortisol if Cushing’s or Addison’s is suspected.

Advanced Clinical Metrics

• Penile-Brachial Pressure Index (PBPI): A PBPI <0.6 is strongly suggestive of a vascular cause.
• Nocturnal Penile Tumescence (NPT): Differentiates psychogenic (normal NPT) from organic (impaired NPT). The "Postage Stamp Test" is a low-cost screening alternative.
• Duplex Doppler Ultrasonography: Measures peak systolic velocity and end-diastolic velocity following vasodilator injection to distinguish arterial insufficiency from venous leak.
• Neuro-Diagnostic Studies: Sacral reflex latency time and Somatosensory Evoked Potential (SSEP) studies for diagnosing sacral nerve injury or MS.

9. Diagnostic Algorithm of ED

1. Substance Screening: History of alcohol, nicotine, or drug ingestion (Beta-blockers, SSRIs, Tricyclics)? If yes, address substance or switch medications .
2. Endocrine Assessment: Evaluate secondary sex characteristics. If absent, evaluate for Fröhlich’s syndrome or Klinefelter’s syndrome.
3. Urologic Evaluation: Abnormalities found (Peyronie’s, atrophied testes, Prostatitis, Leriche’s)? 
4. Neurologic Evaluation: Evidence of Diabetic Neuropathy, MS, or spinal lesions? 
5. Final Differentiation: If examinations are normal, diagnose Psychogenic ED or age-related decline; confirm via NPT.

10. Treatment of Erectile Dysfunction

Lifestyle Modification

• Exercise: ≥18 metabolic equivalent (MET) hours/week is associated with significantly better sexual function.
• Weight Loss and Smoking Cessation: Effective in restoring function in up to one-third of obese patients.

Pharmacological Treatment

PDE5 Inhibitors (First-Line Therapy): PDE5 inhibitors competitively inhibit the catabolism of cGMP. They require sexual stimulation to initiate the NO cascade.

• Orodispersible vardenafil (ODT) tablet appears to have a more rapid onset of action (can be taken 30 minutes before sexual activity) and is effective when taken in the fed state.
• Daily, low-dose tadalafil administration eliminates the concern about onset and duration of action.

Second-Line Therapy

• Vacuum Erection Devices (VED): Effective in 60–70% of cases. Clinical "pearl": VEDs may be used in combination with PDE5 inhibitors to augment results.
• Intracavernosal Injections: Alprostadil or Trimix (Alprostadil, Phentolamine, Papaverine). Trimix is favored for its ability to be finely titrated to the patient's specific hemodynamic response.
• Intraurethral Alprostadil: Medicated pellet (MUSE); less invasive but carries higher rates of penile pain and lower efficacy than injections.

Surgical Treatment

Penile Prosthesis: Reserved for those who fail or are contraindicated for medical therapy. Pre-op protocol: Patients must stop aspirin and NSAIDs for 7 days prior to the procedure.

• Prosthesis Types:
  • Semi-rigid/Malleable: Excellent mechanical reliability; easier for patients with limited dexterity.
  • Inflatable (2-piece or 3-piece): Approximates natural flaccidity/rigidity.
• Surgical Approaches: Penoscrotal, infrapubic, or subcoronal.
• Infection Control: Use of antibiotic-coated implants like InhibiZone (rifampin/minocycline) or Resist (gentamicin/bacitracin) significantly reduces infection risk.
• Maneuvers for Peyronie’s: During prosthesis placement, a "modeling" procedure is performed: forcibly bending the penis opposite the curvature for 90 seconds to fracture fibrotic plaques.

Emerging Technologies

• Low-Intensity Shock Therapy (LIST): Aimed at stimulating angiogenesis; currently under investigation.
• Adipose-Derived Stem Cells (ADSCs): Paracrine action via intracavernous injection; promising but not yet FDA-approved.

11. Special Populations

• Diabetes: Higher risk of ED due to autonomic neuropathy and reduced NO synthase levels. Glycemic control prevents progression but rarely reverses established ED.
• Post-Surgical: ED is a known complication of radical prostatectomy. Nerve-sparing techniques are vital for recovery.
• Hypogonadism: In men with testosterone ≤300 ng/dL, combination therapy of testosterone replacement plus a PDE5i provides superior results over either alone.

12. Complications and Counseling

Priapism Defined as a rigid erection lasting >4–6 hours. It is a medical emergency requiring immediate evacuation of blood to prevent corporal fibrosis and permanent ED.

Patient Counseling Points

1. Nitrate Contraindication: PDE5 inhibitors are strictly contraindicated with any form of nitrates due to the risk of life-threatening hypotension.
2. Proper Usage: Counsel on the requirement for sexual stimulation and the impact of fatty meals on Sildenafil/Vardenafil absorption.

13. FAQs

• What is the first-line treatment? Lifestyle modification and PDE5 inhibitors are the standard of care.
• Can ED be reversed? Yes, through lifestyle changes (weight loss, 18 MET hrs/week exercise), drug substitution, or hormonal replacement in hypogonadal men.
• Is ED a sign of heart disease? Yes. ED and CVD are both expressions of endothelial dysfunction; ED may precede major cardiac events by years.

14. Conclusion

The physician’s role is to utilize ED as a clinical window into the patient's systemic health. By applying a rigorous diagnostic workup—including metrics like PBPI and CV risk stratification—and a stepwise management approach, clinicians can restore sexual function while identifying and mitigating life-threatening cardiovascular risks.

15. Resources: